Implications of Clinical Trial Data on Bispecific T-Cell Receptor Immunotherapy for mUM

Sunandana Chandra, MD, MS, discusses safety and efficacy data from the IMCgp100-202 trial on tebentafusp, and comments on the clinical implications of these data.

Video Player is loading.

Play Video

Play

Mute

Current Time 0:00

/

Duration 3:14

Loaded: 0%

0:00

Stream Type LIVE

Seek to live, currently behind liveLIVE

Remaining Time -3:14

 

1x

Playback Rate

Chapters

• Chapters

Descriptions

• descriptions off, selected

Captions

• captions settings, opens captions settings dialog
• captions off, selected

Audio Track

• en (Main), selected

Fullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

Text

ColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-Transparent

Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparent

Window

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque

Font Size

50%75%100%125%150%175%200%300%400%

Text Edge Style

NoneRaisedDepressedUniformDropshadow

Font Family

Proportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps

Reset restore all settings to the default valuesDone

Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

EP: 1.How Uveal Melanoma Differs from Cutaneous Melanoma

EP: 2.Common Symptoms of Uveal Melanoma and the Typical Diagnostic Journey of the Patient

EP: 3.Historic and Current Treatment Options for mUM

Now Viewing

EP: 4.Implications of Clinical Trial Data on Bispecific T-Cell Receptor Immunotherapy for mUM

EP: 5.Patient Eligibility and Logistical and Safety Considerations for Tebentafusp Treatment in mUM

EP: 6.An Expert’s Experience in Prescribing Tebentafusp and Other Therapies for mUM and a Commentary on Patient Education and Resources

EP: 7.Treatment Options for Patients with mUM Who Are Ineligible for Bispecific T-Cell Receptor Immunotherapy

EP: 8.Advice for Patients Living with Metastatic Uveal Melanoma

Related Videos

The Future of CLL Care: Medical Breakthroughs and Patient-Physician Collaboration

Living Well With CLL: Nutrition, Exercise, and Lifestyle Tips From Patients and Doctors

Fixed-Duration vs Continuous CLL Therapy: Balancing Efficacy, Quality of Life, and Costs

CLL Treatment and Quality of Life: Patient Empowerment and Shared Decision-making

LL Treatment Roadmap: Navigating First-Line Options With Your Doctor

Watchful Waiting in CLL: When Waiting Is Treating

Connections: CLL Diagnosis: A Patient’s Perspective and Physician Insights

Connections: Understanding CLL: Symptoms, Diagnosis, and What Patients Need to Know

Advancing CML Management Towards an Ideal Patient Journey

Unmet Needs and Challenges in Metastatic Uveal Melanoma

Related Content

Advertisement

July 12th 2021

KCCure Patient Surveys Help Providers Understand Patients’ True Experiences During Treatment

Jamie Cesanek

The kidney cancer advocacy organization, KCCure, has been collecting survey data on patient experiences to help bridge the communication gap between providers and patients.

Related Content

CURE Expert ConnectionsUpdates in Diagnosis, Treatment, and Management of Metastatic Uveal Melanoma

CURE Expert Connections

|

Updates in Diagnosis, Treatment, and Management of Metastatic Uveal Melanoma

Advertisement

July 12th 2021

KCCure Patient Surveys Help Providers Understand Patients’ True Experiences During Treatment

Jamie Cesanek

The kidney cancer advocacy organization, KCCure, has been collecting survey data on patient experiences to help bridge the communication gap between providers and patients.